Hepatic Kaposi sarcoma: A case report and review of the literature

Brett Van Leer-Greenberg, Abhisake Kole, Saurabh Chawla

Abstract

Kaposi sarcoma (KS) is an aggressive cancer caused by human herpesvirus-8, primarily seen in immunocompromised patients. As opposed to the well-described cutaneous manifestations and pulmonary complications of KS, hepatic KS is rarely reported before death as most patients with hepatic KS do not manifest symptoms or evidence of liver injury. In patients with acquired immune deficiency syndrome, hepatic involvement of KS is present in 12%-24% of the population on incidental imaging and in approximately 35% of patients with cutaneous KS if an autopsy was completed after their death. Patients with clinically significant hepatic injury due to hepatic KS usually have an aggressive course of disease with hepatic failure often progressing to multi-organ failure and death. Here we report an unusual presentation of acute liver injury due to hepatic KS and briefly review the published literature on hepatic KS.

Key words: Herpesvirus 8; Acquired immune deficiency syndrome-related Kaposi sarcoma; Acquired immune deficiency syndrome hepatopathy; Human; Kaposi sarcoma

© The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Hepatic Kaposi sarcoma (KS) is a clinical presentation that disproportionately affects the human immunodeficiency virus/acquired immune deficiency syndrome (AIDS) population. Up to 34% of patients with AIDS and KS have hepatic involvement. Usually hepatic KS is clinically indolent and diagnosed during autopsy. When clinically significant, hepatic KS presents with evidence of liver injury with elevation in bilirubin and liver enzymes, has characteristic findings on imaging and may progress to liver failure and death. Treatment is indicated in patients with progressive and symptomatic hepatic disease in the absence of other etiologies.

©2017 Baishideng Publishing Group Inc. All rights reserved.
BACKGROUND

KS is an angio proliferative low-grade neoplasm that is associated with human herpesvirus-8 (HHV-8). KS can be codified into different clinical variants depending on the patient cohort and the presentation of the disease[1]. The "classical" form primarily affects men of Ashkenazic Jewish or Mediterranean background and follows an indolent cutaneous course. The "African endemic" form of the disease commonly affects Africans as the name implies, presents with lymphadenopathy and is usually fatal within 1-3 years. The "iatrogenic" form is due to HHV-8 activation caused by medical immunosuppression from treatment of autoimmune disorders or post-organ transplantation. The fourth and most common variant, acquired immune deficiency syndrome (AIDS)-related KS, is rapidly progressive and holds the highest rate of hepatic involvement[2].

The most common presentation of KS is a cutaneous papular disease with lesions on the legs, oral cavity, and genitalia. However, the most common site of visceral organ involvement is the gastrointestinal tract[3]. First described by Moritz Kaposi in 1872, hepatic KS was an autopsy diagnosis that rarely resulted in clinically significant disease or ALI[4]. To further understand hepatic KS, a systematic search of the literature was conducted on PubMed (1954 to 2015), EBSCO HOST (1956 to 2015), the Cochrane Database of Systematic Review, and the OVID interface (1946 to 2015) with comprehensive search terms as documented in Table 1.

EPIDEMIOLOGY

While most herpesviruses are widespread in the adult population, the prevalence of HHV-8 varies with human immunodeficiency virus (HIV) status and exposure risk factors. In the United States, only 5% of HIV uninfected men are seropositive for HHV-8 compared to 25%-60% of HIV-positive men who have sex with men (MSM). These rates are reflective of HHV-8 and HIV co-infection in MSM in other countries as well[5].

AIDS-patients have 20000 times greater risk of developing KS than the general population. Patients on HAART with a CD4 count of < 200 cells/μL are 18.9 times more likely to have KS than those with CD4 ≥ 500 cells/μL[6]. In the era of ARV therapy, improved control of HIV viremia and preserved CD4 T-cell function has lead to an 80% decreased incidence of AIDS-associated KS[5]. AIDS-related KS currently affects < 1% of AIDS patients, compared to 15% in the pre-HAART era[7].

MODES OF TRANSMISSION

Behavioral risk factors for HHV-8 transmission are incompletely understood. Saliva exchange appears to be an important factor with HHV-8 DNA detected in the saliva of 61% of HHV-8-infected MSM[8,9]. With HHV-8 seropositivity higher in the MSM population, commercial sex workers and those with other sexually transmitted infections, a sexual route of transmission has also been proposed. HHV-8 DNA can be isolated from semen and vaginal secretions, but viral load is lower than that found in saliva, calling into question the clinical significance of sexual transmission[10]. HHV-8 seroprevalence in HIV-infected injection drug users is substantially lower than hepatitis B and C rates in HIV-infected MSM[11]. This finding is suggestive that blood exchange through contaminated needle sharing is a less significant route of HHV-8 transmission compared to salivary or sexual contact[12].

HEPATIC INVOLVEMENT

Hepatic KS is typically asymptomatic and rarely diagnosed in life. Therefore the true incidence of hepatic KS is not

REFERENCE

Van Leer-Greenberg B, Kole A, Chawla S. Hepatic Kaposi sarcoma: A case report and review of the literature. World J Hepatol 2017; 9(4): 171-179. Available from: URL: http://www.wjgnet.com/1948-5182/full/v9/i4/171.htm DOI: http://dx.doi.org/10.4254/wjh.v9.i4.171
well-documented and is limited to small case series and reports. Prevalence of hepatic KS has primarily been determined from autopsy series with small sample sizes, which accounts for the wide variation in prevalence reported. In one autopsy series, approximately 34% of AIDS-related KS cases involved the liver while in another report, 8.3% had liver involvement [15,16]. In another retrospective review, hepatic involvement was present in 9 of 41 patients or 22% of cases of AIDS-related KS in post mortem dissection [17]. In this study ante-mortem hepatic KS was suspected in only one patient, in whom a computerized tomography (CT) scan demonstrated hepatosplenomegaly with a confluence of hypodense lesions in the left hepatic lobe. Autopsy confirmed disseminated KS. Schneiderman et al [18] found KS on liver biopsy in 18.6% of AIDS patients making KS the most common hepatic pathological diagnosis caused by AIDS. All of these patients already had a diagnosis of extrahepatic KS at time of biopsy. In contrast, 66% of patients with extrahepatic KS did not manifest hepatic involvement.

As mentioned above, most cases of hepatic KS were not clinically significant. In the study by Schneiderman et al [18], there were no statistically significant differences in transaminases, lactic dehydrogenase, alkaline phosphatase or bilirubin based on liver involvement with KS. However, in the few reported patients with clinically significant disease, a rapid progression to liver and multi-organ failure has been reported, usually with fatal outcomes (Table 2).

In the non-HIV population, the incidence of KS is 0.2% in liver transplant patients from the United States, but the prevalence is higher in patients from Africa, the Middle East or the Mediterranean [19]. KS affected 4.7% of renal transplant patients in Saudi Arabia, 2.4% of recipients in Israel and 0.52% of recipients in France. While there is a well described clinical burden of post-transplant lymphoproliferative disorder including cutaneous and visceral manifestations of KS, there is no described literature of post-transplant hepatic KS.

**PATHOGENESIS OF HHV-8 ASSOCIATED TUMORS**

HHV-8 consists of a large double stranded DNA genome that includes approximately 145 kilobases (kbases) long region encoding all the expressed viral genes, flanked by approximately 20-30 kbases that encode a number of mimicked human genes, several of which have immunologic or angiogenic properties [20,21]. HHV-8 has a tropism for both hematopoietic and non-hematopoietic cells including monocytes, B cells, endothelial cells and also hepatocytes [22]. Endothelial cells appear to be the most important host cells for oncogenic transformation as HHV-8 infection of these cells leads to their long-term proliferation and survival [23]. Similar to other herpesviruses, HHV-8 alternates between two metabolic cycles: Latent infection, where few genes are expressed, and the active lytic infection, where viral replication and multiple gene expression occurs. Lytic replication can be induced by oxidative stress, hypoxia, inflammatory cytokines, chemical exposure or concomitant infections, including HIV [24-27].

In hepatocytes infected with HHV8 genome by DNA polymerase chain reaction amplification, immunohistochemistry demonstrates expression of the transcriptional regulator, latency-associated nuclear antigen-1 (LANA-1) [28]. It has also been directly implicated in oncogenesis because of its ability to bind to the tumour-suppressing protein p53 [29]. Furthermore, hepatocyte growth factor/scatter factor, a kinase that mediates epithelial cell proliferation and angiogenesis [30] has been demonstrated to induce HHV-8 lytic replication, providing a means of KS pro-
Table 2  Outcomes in patients with clinically symptomatic hepatic Kaposi sarcoma

| Age (yr) | Sex | HIV status | CD4 count (cells/mm³) | Liver chemistry profile | Pathology | Treatment | Hospital course + complications |
|----------|-----|------------|-----------------------|-------------------------|-----------|-----------|----------------------------------|
| 45[^30] | M (+) | 192 | T Bil 19.35, ALP 1309, AST 204, ALT 188, GGT 827 | Liver biopsy revealed features of KS with spindle cells, extravasation of red blood cells and haemosiderin deposition. | HHV-8 PCR VL (+) 24000 copies/mL. Paclitaxel, Montelukast | Continued on chemotherapy. Subsequently developed respiratory and renal failure, anaemia and thrombocytopenia from aggressive metastatic KS | |
| 36[^40] | M (+) | 17 | PTI 70 (s), ALT 185, T Bil 23 | Noreoscopy showed bile duct proliferation with diffuse fibrosis with lymphohistiocytic infiltration. | Liposomal doxorubicin | Jaundice, renal failure, fulminant liver failure | |
| 28[^50] | M (+) | NR | Biopsy residues of spindle cells lining portal tracts. Immunoperoxidase staining factor VIII (+) | | Palliative care | Liver function continued to decline and patient died from respiratory failure two weeks later | |
| 38[^60] | M (+) | < 200[^6] | AST 147, ALT 180, ALP 573 | Gross specimen with fibrous thickening of portal tracts and dark red nodules in periportal areas and diffusely infiltrating liver parenchyma. | | Partial cutaneous response, died several weeks later | |
| 40[^70] | M (+) | NR | Reportedly, “normal” | KS present on biopsy of lymph nodes. US with three 7-12 mm hyperechoic nodules. Periportal groups of dilated blood filled cavernous spaces lined by flat endothelial cells and interspersed of spindle cells. Extravasated erythrocytes and minimal hemosiderin deposits | Combination Chemotherapy, NOS | Complete remission of cutaneous lesions and reduction in size of two of the lesions with the third not visible. Readmitted six months later for severe relapse of cutaneous KS. Reinitiated chemotherapy with rapid deterioration and death within one month Presented with jaundice and acute liver injury with a cholestatic pattern, progressed to fulminant hepatic failure and ultimately death | |
| 48[^80] | M (+) | 8 | TBili 20.0, ALP 947, AST 186, ALT 155, INR 1.9 | Liver biopsy was Cytokeratin-7 and HHV-8 staining positive. | Ganciclovir and Rituximab | Primary hepatic manifestations without cutaneous lesions. Persistent abdominal pain after treatment. Progressed to cutaneous lesions six weeks after treatment. Lost to follow-up | |
| 44[^90] | M (+) | CD4/CD8 ratio 0.08 | Lapscopy demonstrated enlarged liver with multiple purple 2-3 mm nodules, Biopsy demonstrated spindle cells, vascular slits, extravasated red cells and lymphocytic infiltration. | Platinum based chemotherapy, NOS | | |

1Less than 200, not otherwise reported. M: Male; F: Female; TBili: Total Bilirubin (units, mg/dL); ALP: Alkaline phosphatase (units, IU/L); AST: Aspartate transaminase (IU/L); ALT: Alanine transaminase (IU/L); GGT: Gamma glutamyl transpeptidase (units, IU/L); HHV-8: Human herpes virus-8; PCR: Polymerase chain reaction; VL: Viral load; IHC: Immunohistochemistry; NR: Not reported; NOS: Not otherwise specified; US: Ultrasound; KS: Kaposi sarcoma.

**DIAGNOSIS OF KS**

A full integumentary survey including oral and rectal examination quantifying extent of disease should be completed in patients with suspected KS. Cutaneous or visceral biopsy is required for diagnosis. On gross pathology, there are usually multiple, grossly irregular, variable sized red-brown spongiform nodules seen in the periportal connective tissue[^31]. Histopathologic features of disease include thin walled vascular formations and inflammatory infiltration. Spindle cell formation is also characteristic of angio proliferative HHV-8-infected cells that have undergone reprogramming of vascular endothelium and tumorigenesis[^32]. Immunohistochemical staining is characteristic for HHV-8 LANA expression within the spindle cell formation[^33]. Immunohistochemistry staining for endothelial cell markers factor VIII, CD31, CD34 and lymphatic vessel endothelial receptor 1 further corroborate a diagnosis of KS[^34].

Further investigation of visceral KS is warranted in the presence of adenopathy or occult bleeding. Patients with cutaneous KS and iron deficiency anemia, fecal occult blood or gastrointestinal symptoms warrant GI endoscopic evaluation. Patients with cutaneous KS and concurrent adenopathy should receive CT of the chest, abdomen, and pelvis to evaluate for visceral KS and HHV-8-related lymphoproliferative disorders including primary effusion lymphoma, Castleman disease, and plasmablastic lymphoma[^35].

**KS STAGING AND PROGNOSIS**

As KS is a disseminated angio proliferative virally mediated malignancy, classic tumor, node, metastasis staging as used in other cancers does not accurately prognosticate disease or dictate treatment. AIDS Clinical Trials Group (ACTG) Oncology Committee has codified staging of AIDS-associated KS[^36]. The ACTG staging system risk stratifies patients low risk (0) or high risk (1) based on three criteria: Tumor burden (T), immune status (I), and systemic illness (S). For tumor burden, risk (T1) is defined by presence of extensive cutaneous, oral disease or visceral disease. For immune status, poor risk (I1) is defined by CD4 count of less than 150 cells/μL. For
systemic illness, poor risk (S1) is defined by the presence of constitutional symptoms, poor performance status, or other opportunistic infections. While these criteria were validated in the pre-ART era, post-ART therapy, a CD4 cutoff of 100 cells/mm³ has an unclear role in predicting mortality.\[38,39\]

IMAGING IN HEPATIC KS

Hepatic KS has characteristic findings on individual imaging modalities that can help delineate clinically significant disease. Abdominal ultrasound imaging of the liver can demonstrate inhomogeneous cystic lesions with hyperechoic bands and nodules along the peripheral branches of portal veins. Likewise, computed tomography of the abdomen is characteristic for inhomogeneous hepatomegaly with multiple small hypodense nodules, often in the perportal area.\[40\] (Figure 4). Mild hepatomegaly is a non-specific finding in 19% of patients with AIDS-related KS.\[41\] MRI shows hyperintense nodules on T1-weighted in-phase imaging and hypointense nodules on T1-weighted out-of-phase imaging (Figure 5). Neither T2-weighted imaging nor hypointense nodules on T1-weighted out-of-phase imaging have any specific findings in hepatic KS.\[42\]

Image guided biopsy of hepatic nodules in patients suspected to have liver involvement demonstrate hyaline globules, hemosiderin accumulation, macrovascular steatosis, large fibrotic portal spaces, bile duct ectasia, neoductogenesis and spindle cells with large, irregular nuclei. Staining of the perinodular tissues is positive for CD31, CD34 and factor VII as can be seen in extrahepatic KS as well.

TREATMENT

As shown in Table 2, hepatic KS is predominantly manifested in patients with HIV/AIDS. While overall HIV mortality is improving in the era of ARV therapy, patients with AIDS-associated KS have an increased risk of death, compared to HIV controls, irrespective of CD4 count.\[43\] HIV-infected patients initiating ARV commonly have progression of their KS lesions.\[44\] However, long term ARV therapy is associated with a reduced incidence of KS. Guidelines currently recommend correcting underlying immunodeficiency by treating AIDS with ARV therapy. Studies indicate that control of KS progression is related to the degree of control of HIV, rather than the specific cART regimen utilized.\[45\] Beyond ARVs, a variety of systemic therapies may be used in KS. Usualy systemic therapy is indicated in progressive disease, with symptomatic visceral involvement, in the presence of immune reconstitution inflammatory syndrome (IRIS) or with extensive cutaneous involvement. These strategies are not specific to hepatic dysfunction in the setting of KS.

Radiotherapy is a well-established treatment and has a robust clinical response for classic nodular KS but tends to be a palliative approach. While it may be a good modality for superficial lesions, electron beam radiation therapy (EBRT) has limited penetration below the dermis; deeper or unresponsive KS may be treated with standard non-EBRT approaches.\[46\]

Retinoid products appear to inhibit IL-6, a cytokine implicated in KS pathogenesis, and have an antiproliferative effect on KS lesions.\[47\] Application of altretinoin can reduce cutaneous lesions of both classic and HIV-KS but has no role in systemic disease.\[48\]

The role of chemotherapy in addition to standard antiretroviral therapy has been explored. A meta-analysis of studies demonstrated that although chemotherapy in addition to ARVs did not have a mortality benefit, it did reduce disease progression.\[49\] Current first-line therapy for advanced AIDS-KS is liposomal anthracyclines, including pegylated liposomal doxorubicin (PLD). In a randomized control trial (RCT), PLD demonstrated superior to previous conventional chemotherapy, bleomycin and vincristine with 58.7% vs 23.3% (P < 0.001) response rate and a decreased adverse event rate (10.7% vs 26.7%)\[50\]. Another RCT of liposomal daunorubicin versus doxorubicin, bleomycin and vincristine showed no statistical difference in response rate or disease progression (25% vs 28%)\[51\]. When the analysis was restricted to patients receiving prior zidovudine, however, survival was improved in the liposomal daunorubicin group. Another non-randomized study showed a trend

![Figure 3 Ultrasound image with multiple small round hyperechoic nodules.](Image 308x621 to 486x763)

![Figure 4 Computerized tomography scan enlarged inhomogeneous liver with multiple hypodense lesions.](Image 308x621 to 486x763)
toward mortality benefit with liposomal doxorubicin as compared to bleomycin plus vinblastine, vincristine or ARV monotherapy alone, although this did not reach statistical significance. Interferon-alpha, has an array of antiviral and antiangiogenic properties with efficacy in AIDS-KS, but its use is limited due to hepatotoxicity.

Paclitaxel has systemic response rates from 59%-71% and is approved as second-line treatment for KS. In randomized controls, paclitaxel does not demonstrate benefit over PLD in complete or partial remission and no mortality data were available according to KS staging. Less well tolerated than doxorubicin, adverse events include peripheral neuropathies, cytopenias, and gastrointestinal upset. Third line agents for AIDS related visceral KS include etoposide, bleomycin, vinblastine, and vincristine with overall response rates ranging from 23% to 36%. The median survival times are 11 (6 to 20) mo in the bleomycin only group and 13 (7 to 36) mo in the ABV group. With extensive side effect profiles, including secondary malignancies, these treatment modalities are maintained in resource-limited settings.

Although HAART with or without chemotherapy is the current recommended treatment, novel targets are being explored including inhibitors of angiogenesis and matrix metalloproteinases. These drugs are currently in various phases of clinical trials. Inhibition of HHV-8 replication with agents such as foscarnet and ganciclovir have also been explored.

Finally, it bears mentioning that treatment for HIV/AIDS in patients co-infected with HHV-8 can cause a paradoxical worsening of disease. In the KS AIDS AntiRetroviral Therapy Trial, 23/112 (21%) of co-infected patients receiving ARV therapy developed KS-IRIS, which was defined as a rapid worsening of KS beyond its natural course within 12 wk of initiating ARV therapy. Of those 23 patients, 10 died, 9 of which had visceral KS. Eighteen patients in the study overall (16%) had worsening elevation in their liver enzymes and two patients (1.8%) died of liver failure. In this study, exclusion criteria included HIV-KS patients with direct serum bilirubin > 85 μmol/L or aspartate aminotransferase or alanine aminotransferase > 2.5 times the normal range.

Biologic and targeted molecular therapies may have a supplementary or alternative role in AIDS-KS, but are currently in early stages of clinical trials. In the AIDS Malignancy Consortium, a phase II trial of imatinib with a small sample size showed a partial response in approximately one third of patients. In another study focusing on patients who did not respond to chemotherapy and chimeric antigen receptor T cell therapy, bevacizumab, an anti-vascular endothelial growth-factor monoclonal antibody, had a response rate in again approximately one third of patients. The cytokine, interleukin-12 had a response rate of 71% in small phase I and phase II trials. However, patients were ineligible if they had transaminitis or a history of hepatic disease.

Ongoing studies include a phase II trial for the utility of combined PLD and bevacizumab in the treatment of advanced AIDS-KS and a phase I study for dosing and side effect profile of combination therapy with ipilimumab, a cytotoxic T-lymphocyte antigen 4 antibody and nivolumab, an antibody against programmed cell death 1 for the treatment of advanced KS solid tumors. These trials show that biologic and molecular therapies may have a role in the future as alternative treatment therapy for some patients with AIDS-KS.

Currently, HHV-8 infection cannot be eradicated but long-term remission is feasible. Treatment is indicated in patients with progressive hepatic disease in the absence of other etiologies.

CONCLUSION

Hepatic KS is a clinical presentation that disproportionately effects the HIV/AIDS population. Up to 34% of patients with AIDS and KS have hepatic involvement. It is rarely clinically significant and often diagnosed during autopsy, but can cause liver injury or even fatal liver failure, as demonstrated in the case presentation above and case series in Table 2. In an immune compromised patient with ALI or failure, a thorough skin exam in addition to abdominal imaging and biochemical testing should be pursued and a diagnosis of hepatic KS should be considered. Treatment of hepatic KS does not differ

Figure 5 SPAIR and T2 images Kaposi sarcoma on magnetic resonance imaging.
REFERENCES

1. Taconi D, Vergori A, Lapini L, Magnolfi A, Camevali A, Caremanti M. Hepatic Kaposi's sarcoma in a patient affected by AIDS: Correlation between histology and imaging. J Ultrasound 2012; 15: 215-219 [PMID: 23730384 DOI: 10.1016/j.jus.2012.10.004]

2. Martin RW, Hood AF, Farmer ER. Kaposi sarcoma. Medicine (Baltimore) 1993; 72: 245-261 [PMID: 8341141 DOI: 10.1097/00005792-199307000-00004]

3. Restrepo CS, Martinez S, Lemos JA, Carrillo JA, Lemos DF, Ojeda P, Koshy P. Imaging manifestations of Kaposi sarcoma. Radiographics 2006; 26: 1169-1185 [PMID: 16844940 DOI: 10.1148/rg.264055129]

4. O'Brien PH, Brasfield RD. Kaposi's sarcoma. Cancer 1966; 19: 1497-1502 [PMID: 100021097-0142[19661119]: 11-1497: AID-CANCER28820191106-3.3.0-C2-2-H]

5. Casper C, Wald A, Pauk J, Tabet SR, Corey L, Celum CL. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis 2002; 185: 990-993 [PMID: 11902325 DOI: 10.1086/396065]

6. Giuliani M, Cordiali-Fei P, Castilletti C, Di Carlo A, Palamara M. Liver specific disease, and further investigation is warranted.

7. Amin MM, Banage F, Nzaro E, Kataha P, Dodero TJ, Pellett PE, Lackritz EM. Transmission of human herpesvirus 8 by blood transfusion. N Engl J Med 2006; 355: 1311-1318 [PMID: 17005590 DOI: 10.1056/NEJMoa055090]

8. Niedt GW, Schinella RA. Acquired immunodeficiency syndrome. Clinicopathologic study of 56 autopsies. Arch Pathol Lab Med 1985; 109: 727-734 [PMID: 2990378]

9. Lemlich G, Schwam L, Lebowi M. Kaposi’s sarcoma and acquired immunodeficiency syndrome. Postmortem findings in twenty-four cases. J Am Acad Dermatol 1987; 16: 319-325 [PMID: 3029191 DOI: 10.1016/0278-2046(87)90043-7]

10. Antinori S, Ridolo AL, Esposito R, Vago L, Moroni M. Liver involvement in AIDS-associated malignancies. J Hepatol 1994; 21: 1145-1146 [PMID: 7699243 DOI: 10.1016/S0168-8278(05)80634-8]

11. Schneiderman DJ, Arenson DM, Cello JP, Margaritton W, Weber TE. Hepatic disease in patients with the acquired immune deficiency syndrome (AIDS). Hepatology 1987; 7: 925-930 [PMID: 2820858 DOI: 10.1002/hep.184070522]

12. Sharma S, Gurakar A, Cenci C, Jabbour N. Avoiding pitfalls: what an endoscopist should know in liver transplantation–part II. Dig Dis Sci 2009; 54: 1386-1402 [PMID: 19085103 DOI: 10.1007/s00412-008-0520-7]

13. Russo JJ, Bohenzky RA, Chen MC, Chen J, Yan M, Maddalena D, Parry JP, Peruzzi D, Edelman IS, Chang Y, Moore PS. Nucleotide sequence of the Kaposi sarcoma-associated herpesvirus (HHV8).

14. Proc Natl Acad Sci USA 1996; 93: 14862-14867 [PMID: 8962146 DOI: 10.1007/00341201047]

15. Moore PS, Bosshoff C, Weiss RA, Chang Y. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science 1996; 274: 1739-1744 [PMID: 8939871 DOI: 10.1126/ science.274.5293.1739]

16. Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med 2000; 342: 1027-1038 [PMID: 10749966 DOI: 10.1056/NEJM2000040643421407]

17. Flores O, Rafi S, Gly S, OLearry JI, Ejek EM, Cesarman E. Transformation of primary human endothelial cells by Kaposi’s sarcoma-associated herpesvirus. Nature 1998; 394: 588-592 [PMID: 970121 DOI: 10.1038/29093]

18. Li X, Feng J, Sun R. Oxidative stress induces reactivation of Kaposi’s sarcoma-associated herpesvirus and death of primary effusion lymphoma cells. J Virol 2011; 85: 715-724 [PMID: 21068240 DOI: 10.1128/JVI.01742-10]

19. Davis DA, Rinderknecht AS, Zoeteweij JP, Aoki Y, Read-Conolle EL, Tosato G, Blauvelt A, Yarchoan R. Hypoxia induces lytic replication of Kaposi sarcoma-associated herpesvirus. Blood 2001; 97: 3244-3250 [PMID: 11342455 DOI: 10.1182/blood.V97.10.3244]

20. Shin HJ, DeCotiis J, Giron M, Palmieri D, Lukac DM. Histone deacetylation classes I and II regulate Kaposi’s sarcoma-associated herpesvirus reactivation. J Virol 2014; 88: 1281-1292 [PMID: 24227836 DOI: 10.1128/JVI.02665-13]

21. Zeng Y, Zhang X, Huang Z, Cheng L, Yao S, Qin D, Chen X, Tang Q, Lv Z, Zhang L, Lu C. Intracellular Tat of human immunodeficiency virus type 1 activates lytic cycle replication of Kaposi’s sarcoma-associated herpesvirus: role of JAK/STAT signaling. J Virol 2007; 81: 2401-2417 [PMID: 17151125 DOI: 10.1128/JVI.0204-24-06]

22. Wheat WH, Cool CD, Morimoto Y, Rai PR, Kirkpatrick CH, Lindenbaum BA, Bates CA, Ellison MC, Serls AE, Brown KK, Routes JM. Possible role of human herpesvirus 8 in the lymphoproliferative disorders in common variable immunodeficiency. J Exp Med 2005; 202: 479-484 [PMID: 16103407 DOI: 10.1084/jem.20050381]

23. Friborg J, Kong W, Hottiger MO, Nabel GJ. p53 inhibition by the LANA protein of KSHV protects against cell death. Nature 1999; 402: 889-894 [PMID: 10622254 DOI: 10.1038/47266]

24. Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad Ser B Phys Biol Sci 2010; 86: 588-610 [PMID: 20551596 DOI: 10.2183/pjab.86.588]

25. Mercader M, Taddeo B, Panella JR, Chandran B, Nickoloff BJ, Foreman KE. Induction of HHV-8 lytic cycle replication by inflammatory cytokines produced by HIV-1-infected T cells. Am
1. **2014;** Pinzone MR, Nunnari G, Martellotta F, Lleshi A, Guarnaccia R, Dognini J, de Pascalis G, Caruso C, Lee S, Von Roenn J, Tulpule A, Dezube BJ, Kotner LM, Doyle TB. Periportal contrast enhancement of major vessels of abdominal CT in acquired immunodeficiency syndrome. *J Pathol* 2000; 156: 1961-1971 [PMID: 10854219 DOI: 10.1016/S0003-8440(99)00569-9]

2. **Buetow PC, Buck JL, Ros PR, Goodman ZD. Malignant vascular tumors of the liver: radiologic-pathologic correlation. Radiographics 1994; 14: 153-166; quiz 167-168 [PMID: 8120408 DOI: 10.1148/rtg341.1.8120408]

3. **Hong YK, Foreman K, Shin JW, Hirakawa S, Curry CL, Sage DR, Libermann T, Dezupe BJ, Fingeroth JD, Detmar M. Lymphatic reprogramming of blood vascular endothelium by Kaposi sarcoma-associated herpesvirus. *Nat Genet* 2004; 36: 683-685 [PMID: 15222917 DOI: 10.1038/ng1383]

4. **Hammock L, Reisenauer A, Wang W, Cohen C, Birdsong G, Folpe AL. Latency-associated nuclear antigen expression and human herpesvirus-8 polymerase chain reaction in the evaluation of Kaposi sarcoma and other vascular tumors in HIV-positive patients. *Mod Pathol* 2005; 18: 463-468 [PMID: 15578080 DOI: 10.1038/modpathol.3800221]

5. **Pantanowitz L, Otis CN, Dezupe BJ. Immunohistochemistry in Kaposi’s sarcoma. *Clin Exp Dermatol* 2010; 35: 68-72 [PMID: 19874352 DOI: 10.1111/j.1365-2230.2009.03707.x]

6. **Du MQ, Diao TC, Liu H, Ye H, Hansoudi RA, Cabeçadas I, Dong HY, Harris NL, Chan JK, Rees JW, Dogan A, Isaacson PG. KSHV- and EBV-associated germinotropic lymphoproliferative disorder. *Blood* 2002; 100: 3415-3418 [PMID: 12384445 DOI: 10.1182/blood-2002-02-0487]

7. **Krown SE, Metró C, Wenz JC. Kaposi’s sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging criteria. AIDS Clinical Trials Group Oncology Committee. *J Clin Oncol* 1989; 7: 1201-1207 [PMID: 2671281]

8. **Nasti G, Talamini R, Antinori A, Martellotta F, Jacchetti G, Chiodo F, Ballardini G, Stoppini L, Di Perri G, Gena M, Tavio M, Vaccher E, D’Arminio Monforte A, Tirelli U. AIDS-related Kaposi’s Sarcoma: evaluation of potential novel prognostic factors and assessment of the AIDS Clinical Trial Group Staging System in the Haart Era---the Italian Cooperative Group on AIDS and Tumors and the Italian Cohort of Patients Naive From Antiretrovirals. *J Clin Oncol* 2003; 21: 2876-2882 [PMID: 12885004 DOI: 10.1200/JCO.2003.10.162]

9. **Mosam A, Shaik F, Ulrick T, Esterhuizen T, Friedland GH, Scaadden DT, Cohen C, Birdsong G, Folpe AL. Immunohistochemical expression of LMP-1 and EBNA-2 proteins in Kaposi sarcoma: results of a prospective randomized trial of trial of high-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. *J Clin Oncol* 2002; 20: 3236-3241 [PMID: 12149296 DOI: 10.1200/JCO.2002.02.1238]

10. **Northfelt DW, Dezupe BJ, Thomas JS, Miller BJ, Frisch MA, Friedman-Kien A, Kaplan LD, Mamelok RD, Ma J, Lusk RD, Henry DH. Pegylated-liposomal doxorubicin versus doxorubicin, bleomycin, and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. *J Clin Oncol* 1999; 16: 2353-2364 [PMID: 8708728]

11. **Grünnaug M, Bogner JR, Loeh O, Goebel FD. Liposomal doxorubicin in pulmonary Kaposi’s sarcoma: improved survival as compared to patients without liposomal doxorubicin. *Eur J Med Oncol* 1999; 3: 13-19 [PMID: 9512962]

12. **Cianfrocca M, Lee S, Von Roenn J, Tulpule A, Dezupe BJ, Aboulafia DM, Ambinder RF, Lee JY, Krown SE, Sparano JA. Randomized trial of paclitaxel versus pegylated liposomal doxorubicin for the treatment of relapsed or progressive human immunodeficiency virus-associated Kaposi sarcoma: evidence of symptom palliation from chemotherapy. *Cancer* 2010; 116: 3969-3977 [PMID: 20564162 DOI: 10.1002/cncr.25362]

13. **Evans SR, Krown SE, Testa MA, Cooley TP, Von Roenn JH. Phase II evaluation of low-dose oral etoposide for the treatment of relapsed or progressive AIDS-related Kaposi’s sarcoma: an AIDS Clinical Trials Group clinical study. *J Clin Oncol* 2002; 20: 3016-3022 [PMID: 11978136 DOI: 10.1200/JCO.2002.02.1238]

14. **Valls C, Cahuas C, Turell LG, Pruna X. Hepatosplenic AIDS-related Kaposi sarcoma: a cohort study. *PLoS One* 2013; 8: e64392 [PMID: 23753122 DOI: 10.1371/journal.pone.0064392]

15. **Bower M, Fox P, Fife K, Gill J, Nelson M, Gazzard B. Highly active anti-retroviral therapy (HAART) prolongs time to treatment failure in Kaposi’s sarcoma. *AIDS* 1999; 13: 2105-2111 [PMID: 10546664 DOI: 10.1097/00002030-19992020-00014]

16. **Martinez V, Caumes E, Gambotti L, Itah H, Morini JP, Deleuze J, Gorin I, Katlama C, Bricaire F, Dupin N. Remission from Kaposi’s sarcoma on HAART is associated with suppression of HIV replication and is independent of protease inhibitor therapy. *Br J Cancer* 2006; 94: 1000-1006 [PMID: 16570046 DOI: 10.1038/sj.bjc.6603056]

17. **Donato V, Guarneraccia R, Dognini J, de Pascalis G, Caruso C, Bellagamba R, Morrone A. Radiation therapy in the treatment of HIV-related Kaposi’s sarcoma. *Anticancer Res* 2013; 33: 2153-2157 [PMID: 23645769]

18. **Vanni T, Sprinz E, Muchado MW, Santana Rde C, Fonseca BA, Schwartmann G. Systematic treatment of AIDS-related Kaposi sarcoma: current status and perspectives. *Cancer Treat Rev* 2006; 32: 445-455 [PMID: 16860939 DOI: 10.1016/j.ctrv.2006.06.001]

19. **Martellotta F, Berretta M, Vaccer E, Schioppa O, Zanet E, Tirelli U. AIDS-related Kaposi’s sarcoma: state of the art and therapeutic strategies. *Curr HIV Res* 2009; 7: 634-638 [PMID: 19929800 DOI: 10.2174/15660020978937619]

20. **Ghabe OF, Okwundu CI, Dedicat M, Freeman EE. Treatment of severe or progressive Kaposi’s sarcoma in HIV-infected adults. *Cochrane Database Syst Rev* 2014; (8): CD003256 [PMID: 25221796 DOI: 10.1002/14651858.CD003256.pub2]

21. **Stewart S, Jablonsowski H, Goebel FD, Arasteh K, Spittle M, Rios A, Aboulafia D, Gallesch J, Dezupe BJ. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi’s sarcoma. International Pegylated Lipoosomal Doxorubicin Study Group. *J Clin Oncol* 1998; 16: 683-691 [PMID: 9469358]

22. **Gill PS, Wenz J, Scadden DT, Cohen P, Mukwaya GM, von Roenn JH, Jacobs M, Kempin S, Silverberg I, Gonzales G, Rarick MU, Myers AM, Shepherd F, Sawka C, Pike MC, Ross ME. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi’s sarcoma. *J Clin Oncol* 1999; 16: 2353-2364 [PMID: 8708728]

23. **Grünnaug M, Bogner JR, Loeh O, Goebel FD. Liposomal doxorubicin in pulmonary Kaposi’s sarcoma: improved survival as compared to patients without liposomal doxorubicin. *Eur J Med Oncol* 1999; 3: 13-19 [PMID: 9512962]
Catanzaro AT, Steinberg SM, Yarchoan R. Activity of subcutaneous interleukin-12 in AIDS-related Kaposi sarcoma. *Blood* 2006; **107**: 4650-4657 [PMID: 16507779 DOI: 10.1182/blood-2005-11-4455]

National Cancer Institute. Pilot Study of Liposomal Doxorubicin Combined With Bevacizumab Followed by Bevacizumab Monotherapy in Adults With Advanced Kaposis Sarcoma. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: https://clinicaltrials.gov/show/NCT00923936 NLM Identifier: NCT00923936

National Cancer Institute. Nivolumab and Ipilimumab in Treating Patients With HIV Associated Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Available from: URL: https://clinicaltrials.gov/show/NCT02408861 NLM Identifier: NCT02408861

Read PJ, Lucas S, Morris S, Kulasegaram R. Immune reconstitution inflammatory syndrome Kaposi sarcoma in the liver manifesting as acute obstructive hepatitis: another potential role for montelukast? *Int J STD AIDS* 2013; **24**: 156-158 [PMID: 24400347 DOI: 10.1177/0956462412472819]

Heunge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. *Lancet* 1993; **342**: 497 [PMID: 8102452 DOI: 10.1016/0140-6736(93)91624-U]

Towers MJ, Withers CE, Rachlis AR, Pappas SC, Kolin A. Ultrasound diagnosis of hepatic Kaposi sarcoma. *J Ultrasound Med* 1991; **10**: 701-703 [PMID: 1766044]

Luburich P, Bru C, Ayuso MC, Azón A, Condom E. Hepatic Kaposi sarcoma in AIDS: US and CT findings. *Radiology* 1990; **175**: 172-174 [PMID: 2179988 DOI: 10.1148/radiology.175.1.2179988]

Van Leer-Greenberg B, Pham T, Spence L, Berger S, Chawla S. Hepatic Kaposi Sarcoma: An Uncommon Etiology of Acute Liver Injury in AIDS. Georgia Gastroenterology and Endoscopy Society Meeting, 2015

Hasan FA, Jeffers LJ, Welsh SW, Reddy KR, Schiff ER. Hepatic involvement as the primary manifestation of Kaposi's sarcoma in the acquired immune deficiency syndrome. *Am J Gastroenterol* 1989; **84**: 1449-1451 [PMID: 2816878]

P- Reviewer: Baddour N, Cohan M, Zhang Q S- Editor: Ji FF L- Editor: A E- Editor: Li D
